Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amitriptyline/ketamine - Immune Pharmaceuticals

Drug Profile

Amitriptyline/ketamine - Immune Pharmaceuticals

Alternative Names: AmiKet; Amiket™ Nano; EpiCept™ NP-1; Ketamine/amitriptyline; NP-1

Latest Information Update: 09 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc; National Cancer Institute (USA)
  • Class Cyclohexanes; Dibenzocycloheptenes; Non-opioid analgesics; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 1 adrenergic receptor antagonists; NMDA receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 07 Aug 2017 Amitriptyline/ketamine remains available for licensing as of 07 August 2017 (http://immunepharmaceuticals.com)
  • 16 Sep 2016 Immune Pharmaceuticals enters into a Binding agreement with Novel Pain Therapeutics to fund Maxim Pharmaceuticals
  • 18 Jul 2016 Immune Pharmaceuticals amends its option agreement with Novel Pain Therapeutics for Peripheral neuropathic pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top